Biomarkers in lower respiratory tract infections

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 6, 2010, Pages 501-507

  Blasi, Francesco ^a   Stolz, Daiana ^b   Piffer, Federico ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarkers; Diagnosis; LRTI; Prognosis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROADRENOMEDULLIN; PROCALCITONIN; PROVASOPRESSIN; UNCLASSIFIED DRUG; VASOPRESSIN;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; LOWER RESPIRATORY TRACT INFECTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; HUMANS; PNEUMONIA; PROGNOSIS; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; VASOPRESSINS;

EID: 78649331348     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.04.007     Document Type: Article

References (54)

1. Biomarkers working group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
2. Almirall J., Bolibar I., Toran P., et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
3. Flanders S.A., Stein J., Shochat G., et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004, 116:529-535.
4. Holm A., Nexoe J., Bistrup L.A., et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract 2007, 57:547-554.
5. Stolz D., Christ-Crain M., Gencay M.M., et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly 2006, 136:434-440.
6. Boussekey N., Leroy O., Georges H., et al. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005, 33:257-263.
7. Polzin A., Pletz M., Erbes R., et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003, 21:939-943.
8. Muller B., Harbarth S., Stolz D., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, 7:10.
9. Oppert M., Reinicke A., Muller C., et al. Elevations in procalcitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation 2002, 53:167-170.
10. Duflo F., Debon R., Monneret G., et al. Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology 2002, 96:74-79.
11. Gibot S., Cravoisy A., Levy B., et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004, 350:451-458.
12. Ramirez P., Garcia M.A., Ferrer M., et al. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J 2008, 31:356-362.
13. Horonenko G., Hoyt J.C., Robbins R.A., Singarajah C.U., et al. Soluble triggering receptor expressed on myeloid cell-1 is increased in patients with ventilator-associated pneumonia - a preliminary report. Chest 2007, 132(1):58-63.
14. Anand N.J., Zuick S., Klesney-Tait J., et al. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in Bal fluid of patients with pulmonary infiltrates in the ICU. Chest 2009, 135(3):641-647.
15. Phua J., Koay E.S.C., Zhang D., et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur Respir J 2006, 28:695-702.
16. Oudhuis G.J., Beuving J., Stobberingh E.E., et al. Soluble triggering receptor expressed on myeloid cells-1 in bronchoalveolar lavage fluid is not predictive for ventilator-associated pneumonia. Intensive Care Med 2009, 35:1265-1270.
17. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005, 26(6):1138-1180.
18. Christ-Crain M., Jaccard-Stolz D., Bingisser R., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607.
19. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin for initiation and discontinuation of antibiotic therapy in community-acquired pneumonia - a randomized trial [ISRCTN04176397]. Am J Respir Crit Care Med 2006, 174(1):84-93.
20. Huang D., Weissfeld L.A., Kellum J.A., et al. GenIMS investigators: risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008, 52:48-58.
21. Kruger S., Ewig S., Marre S., et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008, 31:349-355.
22. Kruger S., Papassotiriou J., Marre R., et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia - results from the German competence network. Intensive Care Med 2007, 33:2069-2078.
23. Christ-Crain M., Morgenthaler N.G., Stolz D., et al. Proadrenomedullin to predict severity and outcome in community acquired pneumonia. Crit Care 2006, 10:R96.
24. Huang D.T., Angus D.C., Kellum J.A., et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009, 136(3):823-831.
25. Bruns A.H.W., Oosterheert J.J., Hak E., et al. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008, 32:726-732.
26. Menéndez R., Martinez R., Reyes S., et al. Stability in community-acquired pneumonia: one step forward with markers?. Thorax 2009, 64:987-992.
27. Mirsaeidi M., Peyrani P., Aliberti S., et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest 2009 Oct 16, [Epub ahead of print].
28. Povoa P., Coelho L., Almeida E., et al. C-reactive protein as a marker of ventilator associated pneumonia resolution: a pilot study. Eur Respir J 2005, 25:804-812.
29. Seligman R., Meisner M., Lisboa T.C., et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006, 10:R125.
30. Luyt C.E., Guerin V., Combes A., et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005, 171:48-53.
31. Hillas G., Vassilakopoulos T., Plantza P., et al. CRP and PCT as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J 2009 Aug 28, [Epub ahead of print].
32. Cazzola M., MacNee W., Martinez F.J., on behalf of the American Thoracic Society/European Respiratory Society task force on outcomes of COPD, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-468.
33. Man S.F.P., Connett J.E., Anthonisen N.R., et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853.
34. Dahl M., Vestbo J., Lange P., et al. C-reactive protein as a predictor of prognosis in COPD. Am J Respir Crit Care Med 2007, 175:250-255.
35. de Torres J.P., Pinto-Plata V., Casanova C., et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008 Jun, 133(6):1336-1343.
36. Hurst J.R., Donaldson G.C., Perera W.R., et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:867-874.
37. Perera W.R., Hurst J.R., Wilkinson T.M.A., et al. Inflammatory changes, recovery and recurrence at COPD exacerbations. Eur Respir J 2007, 29:527-534.
38. Stolz D., Christ-Crain M., Morgenthaler N., et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007, 131:1058-1067.
39. Stolz D., Christ-Crain M., Morgenthaler N.G., et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008, 134:263-272.
40. Aliberti S., Blasi F., Zanaboni A.M., et al. Duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia. Eur Respir J 2009 Nov 19, [Epub ahead of print].
41. Schetz P., Christ-Crain M., Thomann R., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections - the ProHOSP randomized controlled trial. J Am Med Assoc 2009, 302(10):1059-1066.
42. Stolz D., Smyrnios N., Eggimann P., et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34:1364-1375.
43. Papi A., Bellettato C.M., Braccioni F., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006, 173:1114-1121.
44. Martinez F.J., Curtis J.L. Acute exacerbations of COPD: part 1; definition and etiology. J COPD Management 2006, 7:4-10.
45. Anthonisen N., Manfreda J., Warren C., et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
46. Stockley R.A., O'Brien C., Pye A., et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000, 117:1638-1645.
47. Allegra L., Blasi F., Diano P.L., et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 2005, 99:742-747.
48. Soler N., Agustí C., Angrill J., et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007, 62(1):29-35.
49. van der Meer V., Neven A.K., van den Broek P.J., et al. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005, 331:26-31.
50. Stolz D., Christ-Crain M., Bingisser R., et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007, 131:9-19.
51. Martinez F.J., Curtis J.L. Procalcitonin-guided antibiotic therapy in COPD exacerbations-closer but not quite there. Chest 2007, 131:1-2.
52. Niederman M.S. Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis 2008, 47:S127-S132.
53. Jereb M., Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien KlinWochenschr 2006, 118:170-174.
54. Mueller C., Müller B., Perruchoud A.P. Biomarkers: past, present, and future. Swiss Med Wkly 2008, 138(15-16):225-229.